Yaojia Ma
Overview
Explore the profile of Yaojia Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kojima R, Nakamoto S, Kogure T, Ma Y, Ogawa K, Iwanaga T, et al.
World J Virol
. 2023 Jul;
12(3):209-220.
PMID: 37396703
Background: Hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC). HBV DNA can get integrated into the hepatocyte genome to promote carcinogenesis. However, the precise mechanism by...
2.
Qiang N, Ao J, Nakamura M, Chiba T, Kusakabe Y, Kaneko T, et al.
Int Immunopharmacol
. 2023 Mar;
118:110068.
PMID: 37001386
Enhancer of zeste homolog 2 (EZH2), a core component of polycomb repressive component 2 is overexpressed in a variety of cancers and recognized as a therapeutic target molecule. However, EZH2...
3.
Ogawa K, Chiba T, Nakamura M, Arai J, Zhang J, Ma Y, et al.
Anticancer Res
. 2023 Feb;
43(3):1043-1052.
PMID: 36854524
Background/aim: MHC-class I-related chain A (MICA) functions as a ligand for natural killer group D, an activating receptor on natural killer (NK) cells, and its expression correlates with the carcinogenesis...
4.
Iwanaga T, Chiba T, Nakamura M, Kaneko T, Ao J, Qiang N, et al.
Biochem Biophys Res Commun
. 2022 Dec;
642:192-200.
PMID: 36586187
Transforming growth factor (TGF)-β/Smad pathway is implicated in the pathogenesis of liver fibrosis, a condition characterized by excessive deposition of extracellular matrix (ECM) proteins such as collagen in response to...
5.
Ma Y, Nakamoto S, Ao J, Qiang N, Kogure T, Ogawa K, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36233317
A functional cure of hepatitis B virus (HBV) infection or HB antigen loss is rarely achieved by nucleos(t)ide analogs which target viral polymerase. HBx protein is a regulatory protein associated...
6.
Ogawa K, Kanzaki H, Chiba T, Ao J, Qiang N, Ma Y, et al.
J Cancer
. 2022 Jun;
13(8):2656-2661.
PMID: 35711837
Atezolizumab plus bevacizumab (ATZ/BV) treatment is a combined immunotherapy consisting of immune checkpoint inhibitor (ICI) and anti-vascular endothelial growth factor monoclonal antibody, which has brought a major paradigm shift in...
7.
Sakuma T, Nakamura M, Chiba T, Iwanaga T, Kan M, Kojima R, et al.
Lab Invest
. 2022 Jun;
102(10):1150-1157.
PMID: 35643859
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease worldwide. Patients with NAFLD often suffer steatohepatitis, which can progress to cirrhosis and hepatocellular carcinoma. The...
8.
Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, et al.
J Cancer
. 2021 Apr;
12(9):2694-2701.
PMID: 33854629
Hepatocellular carcinoma (HCC) is typically accompanied by abundant arterial blood flow. Although angiogenic growth factors such as Angiopoietin 2 (Ang2) play a central role in tumor angiogenesis in HCC, the...
9.
Ao J, Chiba T, Shibata S, Kurosugi A, Qiang N, Ma Y, et al.
Biochem Biophys Res Commun
. 2021 Mar;
549:171-178.
PMID: 33676186
Lenvatinib is one of the first-line drugs for patients with advanced hepatocellular carcinoma (HCC) and widely used around the world. However, the mechanisms underlying resistance to lenvatinib remain unclear. In...